Aytu BioPharma appoints Mark Oki as CFO effective Jan 17, 2022; grants 100k inducement shares

AYTU BIOPHARMA, INC

Mark Oki named CFO; annual base salary of $415,000, target bonus 40% of base, and $50,000 signing bonus.
Inducement award of 100,000 restricted shares granted under Nasdaq Rule 5635(c)(4), vesting over three years.
Severance: termination without cause or for good reason triggers base salary, COBRA for 12 months, and vesting.
Change-in-control provision: one times base salary plus target bonus, 12 months COBRA, full equity acceleration.
Oki previously CFO of Vivus and Alexza; brings over 20 years pharma finance experience.

item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Oki

Chief Financial Officer

AYTU · AYTU BIOPHARMA, INC

Effective: 2022-01-17
Filed: January 4, 2022, 6:59 PM ET

On January 4, 2022, Aytu issued a press release announcing the appointment of Mr. Oki as Chief Financial Officer of the Company effective January 17, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Oki was appointed as Chief Financial Officer at AYTU BIOPHARMA, INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 4, 2022, Aytu issued a press release announcing the appointment of Mr. Oki as Chief Financial Officer of the Company effective January 17, 2022.

View on SEC.gov

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-22-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.